Notably, the MDS-related mutations in U2AF1 and SRSF2 have been recently included in the ELN2022 classification [5], emphasizing the reliability of the three-PSMs model in distilling molecular alterations associated with AML. This evidence concerns the gene U2AF1 and myelodysplastic syndrome.